YOLFTbeta
Foghorn Therapeutics Inc

Foghorn Therapeutics Inc

FHTX · NASDAQ · Healthcare / Biotechnology

2.07USD+0.02 (+0.98%)

Price History

Full chart

Market Stats

Previous Close2.05
Open2.04
Day Range1.94 – 2.08
52-Week Range3.27 – 7.61
Volume534.22K
Market Cap213.79M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.92
Dividend Yield0.00%
Beta2.86
50-Day Avg5.34
200-Day Avg5.08

About

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Adrian H. B. Gottschalk
  • Employees106
  • Headquarters99 Coolidge Avenue, Watertown, MA, United States, 02472, USA
  • Websitehttps://foghorntx.com

Leadership

  • Dr. Douglas G. Cole M.D.Founder & Independent Chairman of the Board · b. 1960
  • Mr. Adrian H. B. GottschalkPresident, CEO & Director · b. 1976
  • Dr. Steven F. Bellon Ph.D.Chief Scientific Officer · b. 1965
  • Dr. Alfonso Quintas Cardama M.D.Chief Medical Officer · b. 1971
  • Dr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory Board
  • Mr. Ryan D. MaynardChief Financial Officer · b. 1969
  • Ms. Karin HellsvikChief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations
  • Mr. Michael J. LaCascia J.D.Chief Legal Officer · b. 1965
  • Mr. Saurabh Sewak Ph.D.Vice President of Corporate Development
  • Mr. Carlos CostaChief People Officer · b. 1973

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00430.00K1.32M19.23M34.16M22.60M30.91M
Growth (%)---+206.74%+1357.77%+77.63%-33.83%+36.75%
Cost of Revenue379.00K1.79M57.72M7.51M19.23K109.69M3.12M3.33M
Gross Profit-379.00K-1.79M-57.28M1.32M19.21M34.16M22.60M27.58M
Gross Margin---13322.09%100.00%99.90%100.00%100.00%89.22%
Operating Expense25.67M49.29M11.25M102.05M136.35M142.06M125.28M109.68M
Operating Income-26.05M-51.08M-68.53M-100.73M-117.14M-107.91M-102.68M-82.11M
Operating Margin---15937.44%-7637.15%-609.20%-315.93%-454.31%-265.64%
EBITDA-25.59M-48.80M-67.20M-96.19M-113.82M-90.75M-97.17M-70.95M
EBITDA Margin---15628.84%-7292.42%-591.93%-265.70%-429.90%-229.55%
Net Income-26.34M-51.13M-68.80M-101.32M-108.87M-98.43M-86.62M-74.28M
Net Income Margin---16000.00%-7681.58%-566.23%-288.17%-383.24%-240.33%
R&D21.23M44.36M57.72M80.33M105.62M109.69M94.53M85.47M
R&D as % of Total Revenue--13422.09%6089.84%549.29%321.15%418.23%276.51%
Interest Expense371.00K540.00K979.00K1.91M11.57M---
Interest Expense % of Total Revenue--227.67%144.50%60.16%---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets43.06M22.34M255.59M519.77M404.88M285.92M283.98M198.10M
Total Liabilities82.33M110.36M109.41M422.90M404.77M363.11M329.51M306.60M
Total Equity-39.27M-88.02M146.19M96.87M112.00K-77.19M-45.53M-108.50M
Cash40.02M14.98M92.80M101.14M52.21M80.34M55.45M80.88M
Total Debt7.03M16.63M82.00M58.33M51.51M45.07M37.13M41.27M
Net Debt-32.99M1.65M-10.80M-42.80M-707.00K-35.26M-18.32M-39.61M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-22.65M-46.34M-31.29M-50.25M193.61M-118.11M-100.41M-86.10M
Investing Cash Flow-1.54M-964.00K-108.91M36.17M-244.32M144.45M-29.90M112.04M
Financing Cash Flow51.77M23.97M217.47M22.42M1.76M1.78M105.43M1.02M
Capital Expenditure1.54M968.00K16.18M3.31M1.21M1.22M906.00K50.00K
Free Cash Flow-24.19M-47.30M-47.47M-53.56M192.40M-119.33M-101.31M-86.15M
FCF to OCF106.80%102.09%151.73%106.59%99.38%101.04%100.90%100.06%

Earnings

Report DateSep 2, 2020Dec 4, 2020Mar 18, 2021May 11, 2021Aug 10, 2021Nov 9, 2021Mar 10, 2022May 9, 2022Aug 9, 2022Nov 8, 2022Mar 9, 2023May 8, 2023Aug 4, 2023Nov 2, 2023Mar 7, 2024May 6, 2024Aug 8, 2024Nov 4, 2024Mar 6, 2025May 5, 2025Aug 5, 2025Nov 5, 2025Mar 5, 2026May 7, 2026Aug 6, 2026Nov 4, 2026
EPS Estimate-2.42-2.69-0.45-0.55-0.59-0.59-0.49-0.47-0.41-0.50-0.54-0.72-0.69-0.65-0.76-0.59-0.64-0.43-0.28-0.29-0.32-0.31-0.26-0.31-0.23-0.22
EPS Actual-1.29-3.12-1.86-0.62-0.63-0.71-0.74-0.65-0.66-0.62-0.69-0.73-0.70-0.34-0.57-0.59-0.45-0.31-0.30-0.30-0.28-0.25-0.37-0.29-0.10-
Surprise46.69%-15.99%-313.33%-12.73%-6.78%-20.34%-51.02%-38.30%-60.98%-24.00%-27.78%-1.39%-1.45%47.69%25.00%0.00%29.69%27.91%-7.14%-3.45%12.50%19.35%-41.14%6.45%56.52%-
Timing-Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap213.79M
Enterprise Value105.34M
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.82
Price / Book2005.35
EPS-0.92
Book Value-1.38
Revenue (TTM)36.74M
Gross Profit (TTM)-42.09M
EBITDA-66.35M
Profit Margin-175.78%
Operating Margin-54.79%
Return on Equity-470.38%
Return on Assets-19.92%
Shares Outstanding59.39M
Shares Float28.08M
Beta2.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 11.44
  • Strong Buy
    5
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
76.67%
Insiders
14.13%
Retail / Other
9.20%

Top Institutional Holders

  • Flagship Ventures Management, Inc.
    12.67M21.34%
  • FMR Inc
    6.05M10.18%
  • Bvf Inc
    5.84M9.84%
  • Deerfield Management Co
    4.39M7.40%
  • BlackRock Inc
    2.36M3.98%
  • Euclidean Capital LLC
    1.57M2.65%
  • Vanguard Capital Management, LLC
    1.50M2.52%
  • Geode Capital Management, LLC
    848.17K1.43%
  • Siren, L.L.C.
    720.72K1.21%
  • State Street Corp
    679.79K1.14%
  • Ameriprise Financial Inc
    448.98K0.76%
  • Renaissance Technologies Corp
    406.43K0.68%
  • Candriam Luxembourg S.C.A.
    313.76K0.53%

Top Fund Holders

  • Fidelity Growth Company Fund
    1.83M3.09%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.12M1.88%
  • iShares Russell 2000 ETF
    883.11K1.49%
  • Fidelity Growth Company K6
    503.27K0.85%
  • Fidelity Small Cap Index
    396.86K0.67%
  • Fidelity Select Biotechnology
    351.58K0.59%
  • iShares Russell 2000 Growth ETF
    345.13K0.58%